Investors

 

Key to long-term value: discipline, execution and consistent communication.

Print pageEmail pageRSS feedsShare page

News releases

The news releases listed below were believed to be accurate in all material respects at the time of original issuance. Please note that we do not intend, and assume no obligation, to update, correct, or otherwise modify any of these press releases for events that occur subsequent to the original release date. We suggest you review the more recent press releases in order to receive the most current information made available by ARIAD.

Keyword Search
 
2016 | 2015 | 2014 | 2013
DateTitle 
02/10/16ARIAD to Present at the RBC Capital Markets Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 10, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the RBC Capital Markets Healthcare Conference being held in New York City. Paris Panayiotopoulos, president and chief executive officer, will provide an overview of the Company’s business on Wednesday, February 24, at 4:35 p.m. (ET). The ARIAD presentation at the RBC Capital Markets Healthcare Conference ... 
Printer Friendly Version
02/02/16ARIAD to Webcast Conference Call on Fourth Quarter and Year-End 2015 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 2, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will report its fourth quarter and year-end 2015 financial results on Tuesday, February 23, 2016, before the market opens. Following the announcement, at 8:30 a.m. Eastern Time, company management will host a conference call and webcast discussion of the results and provide a general corporate update. The live webcast... 
Printer Friendly Version
02/01/16ARIAD Announces FDA Clearance to Begin Clinical Development of AP32788
Internally Discovered Product Candidate Designed to Address Unmet Need in Non-Small Cell Lung Cancer Patients with Specific EGFR and HER2 Kinase Mutations CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 1, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the Company’s Investigational New Drug (IND) application for AP32788, a tyrosine kinase inhibitor (T... 
Printer Friendly Version
01/15/16ARIAD Reports Inducement Grant to New Chief Executive Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 15, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported the grant of an inducement award to its new Chief Executive Officer, Paris Panayiotopoulos. The award was approved by the Compensation Committee and ratified by the full Board of Directors on December 16, 2015, as an inducement material to Mr. Panayiotopoulos’ entering into employment with the Company in accordance with NASDAQ Listing Rule ... 
Printer Friendly Version
01/11/16ARIAD Announces Termination of Shareholder Rights Plan
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 11, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced that its Board of Directors has unanimously approved the termination of the Company’s Section 382 Rights Agreement, or the Rights Plan, originally adopted on October 31, 2013, effective immediately. The Rights Plan and the associated rights expired at 5:00 p.m. EST on January 8, 2016, and will be of no further force or effect. ARIAD shareho... 
Printer Friendly Version
01/10/16ARIAD Announces Election of Alex Denner as Chairman of the Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 10, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the election of Alexander J. Denner, Ph.D., as chairman of its board of directors in a unanimous vote effective January 8, 2016. Dr. Denner joined the ARIAD Board of Directors in February 2014 and most recently led the Board’s search committee to select the Company’s new CEO Paris Panayiotopoulos. This Smart News Release features multime... 
Printer Friendly Version
01/08/16ARIAD and Otsuka Submit New Drug Application in Japan for Ponatinib
Submission based on Phase 2 trial in Japanese patients with refractory chronic myeloid leukemia (CML) or Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 8, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that its partner Otsuka Pharmaceutical Co., Ltd. (Otsuka) has submitted a new drug application (NDA) to the Japanese Pharmaceuticals and Medical Devices A... 
Printer Friendly Version